HIMS Hims Hers Health Inc
Company Analysis
Latest News
🟢 Hims Hers Health is trading 4.04% up today as healthcare shares rise on strong earnings
Hims Hers Health is trading at $28.84, up +4.04%, alongside a healthcare-sector rally attributed to strong earnings and raised guidance from major healthcare...
🔴 Hims Hers Health is trading 4.3% down after hotter-than-forecast inflation revived rate concerns
Hims Hers Health is trading at $26.52, down 4.33%, as September inflation exceeded forecasts and revived concerns about interest rates staying higher. -...
🔴 Hims Hers Health is trading 4.01% down today as hotter-than-expected inflation lifts rate-hike bets
Hims Hers Health is trading at $28.52, down 4.01%, as hotter-than-expected September inflation raised concerns about interest rates staying higher. - Reuters...
🔴 Hims Hers Health is trading 4.14% down amid securities class-action overhang
Hims Hers Health is trading 4.14% down at $29.37, with coverage linking the decline to ongoing class-action legal overhang. - The class action is tied to...
Hims & Hers Health Rated a Buy with a $41 Fair Value Estimate
A Seeking Alpha analysis assigned Hims & Hers Health (HIMS) a "buy" rating. The analysis set a fair value estimate of $41 per share. The report suggests the...
Hims & Hers Launches Hers in Australia After Rebranding Juniper
Hims & Hers Health has officially launched its Hers brand in Australia, expanding its global presence. The launch rebrands Juniper, a women’s health platform...
Hims Shares Jump 10% on Oscar Health Marketplace Talks, but Is the Rally Built on Old News?
Shares of Hims & Hers Health surged 10.2% to $30.93 on Friday, reversing a week of drift, after renewed attention to discussions between the telehealth company...
🟢 Hims Hers Health is trading 10% up today amid reported Lucie Health Marketplace talks
Hims Hers Health is trading 10.21% up now at $30.93, with supplied alert context linking the move to Oscar Health CEO Mark Bertolini’s discussion of talks to...
Hims & Hers in Talks with Oscar Health for New Retail Drug Marketplace
Oscar Health CEO Mark Bertolini revealed talks for a potential partnership with Hims & Hers Health (HIMS). HIMS shares rose following the announcement. The...
🟢 Hims Hers Health is trading 4.7% up
Hims Hers Health is trading 4.67% higher at $29.37 on October 9, 2026, rebounding from its October 8 close of $28.06; no clear company-specific reason for the...
🔴 Hims Hers Health falls 4.1% — Healthcare Stocks Fall on Broad Market Geopolitical and Rate Fears
With Healthcare (XLV) down 1.5%, this looks like a sector-led move rather than a company-specific surprise. The healthcare sector declined, mirroring a wider...
🟢 Hims Hers Health is trading 4.63% up
Hims Hers Health is trading 4.63% up at $30.03 on September 30, 2026, with no clear catalyst identified. - Available searches did not identify a...
Hims & Hers Extends AI-Native Care Platform to Weight Loss Division
Hims & Hers Health Inc. expands its AI-native care platform to Hims weight loss members. This platform leverages technology previously launched for other...
🔴 Hims Hers Health is trading 4.3% down today as crude oil and Treasury yields pressure equities
Hims Hers Health is trading 4.3% down at $29.12 amid market weakness as crude oil and Treasury yields weigh on risk appetite. - The Nasdaq Composite fell...
🟢 Hims Hers Health is trading 4.16% up today as broader risk appetite strengthens
Hims Hers Health is trading at $30.57, up 4.16%, as broader risk-on sentiment supports the move. - On September 21, 2026, it closed at $29.35, up 4.86%. -...
🟢 Hims Hers Health is trading 4.25% up today amid broad risk-on conditions
Hims Hers Health is trading 4.25% up at $29.18, apparently lifted by broad risk-on conditions. - The stock is outperforming its September 18 close of...
🟢 Hims Hers Health is trading 4.11% up today after JPMorgan resumed coverage at Neutral
Hims Hers Health is trading 4.11% up at $28.64 after JPMorgan resumed coverage on September 11, 2026, with a Neutral rating and a $32 price target. - The...
JPMorgan Resumes Hims & Hers Coverage at Neutral, Citing GLP-1 Headwinds
JPMorgan resumed coverage of Hims & Hers Health. The bank assigned a "Neutral" rating and a $32 price target. JPMorgan had suspended coverage in...
Hims & Hers sued over health data leaks and deceptive billing
Robbins Geller Rudman & Dowd LLP filed a class-action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS). The legal action represents investors who...
Hims & Hers enters Australia with GLP-1s, targeting $1 billion revenue
Hims & Hers Health launched its Hims brand in Australia, marking its first entry into the Asia-Pacific market. This expansion supports a strategy to reach $1...